Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir, wherein said elevated serum concentration of the UGT1A1 substrate is not caused by administration of atazanavir.

2. (previously presented) The method of claim 1 wherein the disease or disorder is unconjugated hyperbilirubinemia.

3. (previously presented) The method of claim 1 wherein the UGT1A1 substrate is bilirubin.

4. (previously presented) The method of claim 1 wherein the effective amount of ritonavir is in a range of about 25 to about 1200 mg daily.

5. (currently amended) A method for treating unconjugated hyperbilirubinemia comprising the step of administering an effective amount of ritonavir to a subject in need thereof, wherein said unconjugated hyperbilirubinemia is not caused by administration of atazanavir.

6. (previously presented) The method of claim 5 wherein the effective amount of ritonavir is in a range of about 25 to about 1200 mg daily.

7. (currently amended) A method for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate ~~upon administration of an active pharmaceutical ingredient~~ comprising the step of ~~co-administering~~ administering ritonavir in an

effective amount to a subject in need thereof, wherein said elevated serum concentration of the UGT1A1 substrate is not caused by administration of atazanavir.

8. (previously presented) The method of claim 7 wherein the effective amount of ritonavir is in a range of about 25 mg to about 1200 mg.

9. (currently amended) The method of claim 7, wherein said elevated serum concentration of the UGT1A1 substrate is a result of administration of an active pharmaceutical ingredient to the subject, and wherein the active pharmaceutical ingredient is selected from the group consisting of ~~consisting essentially of~~ indinavir, ~~atazanavir,~~ amphotericin B/cholesteryl sulfate complex, testosterone, interferon beta-1b, bicalutamide, ciprofloxacin, oxaliplatin, floxuridine, gemcitabine hydrochloride, sargramostim, gemtuzumab ozogamicin, vinorelbine tartrate, carboplatin, peginterferon alfa-2B, tacrolimus, aldesleukin, dalfopristin/quinupristin, didanosine and capecitabine.

10. (currently amended) The method of claim 9 ~~claim 7~~ wherein the active pharmaceutical ingredient is indinavir.

11. (canceled)

12. (previously presented) The method of claim 7 wherein the disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate is unconjugated hyperbilirubinemia.

13-18. (canceled)